Jasper Therapeutics (JSPR)
NASDAQ:JSPR
Want to see JSPR full AI Analyst Report?
JSPR Stock Chart & Stats
$1.02
-$10.02(-56.58%)
At close: 4:00 PM EST
$1.02
-$10.02(-56.58%)
Day’s Range― - ―
52-Week Range$0.62 - $7.19
Previous CloseN/A
Volume4.28M
Average Volume (3M)399.98K
Market Cap
$27.60M
Enterprise Value-$11.44M
Total Cash (Recent Filing)$28.69M
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta2.45
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.60
Shares Outstanding27,996,819
10 Day Avg. Volume455,991
30 Day Avg. Volume399,984
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.45
Enterprise Value/Market Cap-0.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit39.43
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$8.13Price Target Upside696.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.86
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyClinical data showed rapid onset and durable symptom reductions with mostly low‑grade, transient adverse events, supporting a competitive efficacy profile for briquilimab.
Market OpportunityFast enrollment in competitor studies highlights a substantial unmet need in chronic spontaneous urticaria, suggesting room for a differentiated product like briquilimab to capture market share.
Safety ProfileOpen‑label results reported no hypopigmentation and low rates of hair color changes, indicating a favorable skin safety profile versus some competitors that experienced treatment discontinuations.
Bears Say
Execution And Timing RiskAdvancement to later‑stage studies hinges on next steps such as dose selection and funding, exposing the program to execution and timing risks if those milestones are delayed.
Financing RequirementProgression to the Phase 2b/3 trial is dependent on securing additional financing, creating a funding risk that could impede planned development activities.
Jasper Therapeutics News
JSPR FAQ
What was Jasper Therapeutics’s price range in the past 12 months?
Jasper Therapeutics lowest stock price was $0.62 and its highest was $7.19 in the past 12 months.
What is Jasper Therapeutics’s market cap?
Jasper Therapeutics’s market cap is $27.60M.
When is Jasper Therapeutics’s upcoming earnings report date?
Jasper Therapeutics’s upcoming earnings report date is May 08, 2026 which is in 3 days.
How were Jasper Therapeutics’s earnings last quarter?
Jasper Therapeutics released its earnings results on Mar 30, 2026. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.796 by $0.476.
Is Jasper Therapeutics overvalued?
According to Wall Street analysts Jasper Therapeutics’s price is currently Undervalued.
Does Jasper Therapeutics pay dividends?
Jasper Therapeutics does not currently pay dividends.
What is Jasper Therapeutics’s EPS estimate?
Jasper Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jasper Therapeutics have?
Jasper Therapeutics has 27,996,819 shares outstanding.
What happened to Jasper Therapeutics’s price movement after its last earnings report?
Jasper Therapeutics reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.796. Following the earnings report the stock price went down -2.667%.
Which hedge fund is a major shareholder of Jasper Therapeutics?
Currently, no hedge funds are holding shares in JSPR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Jasper Therapeutics
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
JSPR Stock 12 Month Forecast
Average Price Target
$8.13
▲(696.57% Upside)
Technical Analysis
Ownership Overview
1.34% Insiders
7.08% Mutual Funds
0.05% Other Institutional Investors
87.19% Public Companies and
Individual Investors